Pricing Log in Create free account

iBio, Inc. (IBIO) vs Kalaris Therapeutics Inc. (KLRS)

iBio, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. iBio, Inc. and Kalaris Therapeutics Inc. are of similar size ($47.8M and $47.6M). Across the 10 metrics below, iBio, Inc. leads on 5 and Kalaris Therapeutics Inc. on 5.

Valuation

Metric IBIO KLRS Biotechnology median
P/E n/m n/m 8.50
P/S 118.71 n/m 9.71
P/B 0.93 0.83 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.19 0.55 0.64
EV/Sales (9.70) n/m 9.21
Earnings yield (44.16%) (101.00%) (33.15%)
Free cash flow yield (30.24%) (85.89%) (25.50%)

Profitability

Metric IBIO KLRS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (65.70%) (79.91%) (56.36%)
Return on assets (54.04%) (46.02%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IBIO KLRS Biotechnology median
Revenue growth (TTM) (66.55%) — 6.02%
EPS growth (last fiscal year) 81.71% 94.50% 30.26%
Revenue growth, 5-year CAGR (42.83%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IBIO KLRS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.85 10.98 4.72
Net debt to EBITDA 2.57 2.54 0.96

Dividend

Metric IBIO KLRS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IBIO KLRS Biotechnology median
Market cap 47.63m 47.83m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack